DCM
SLS icon

DAFNA Capital Management’s SELLAS Life Sciences SLS Stock Holding History

DAFNA Capital Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-31
Closed -$16K – 76
2017
Q3 		$16K Hold
31
– – 0.01% 73
2017
Q2 		$27K Hold
31
– – 0.02% 75
2017
Q1 		$28K Buy
+31
New +$51.3K 0.02% 72

Other funds holding SLS

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

DAFNA Capital Management's SLS Position: Q4 2017 in Review

DAFNA Capital Management sold out of SELLAS Life Sciences (SLS) in Q4 2017, closing a stake of 31 shares — an estimated $16K sold.

DAFNA Capital Management first reported a position in SLS in Q1 2017 and held it in 3 quarters. The position peaked at $28K in Q1 2017. 24 funds tracked by Wall St. Rank hold SLS as of Q4 2017.

  • DAFNA Capital Management reported no remaining SELLAS Life Sciences position as of Q4 2017 after selling out during the quarter.
  • DAFNA Capital Management sold 31 SELLAS Life Sciences shares in Q4 2017, an estimated $16K.
  • DAFNA Capital Management first reported a position in SELLAS Life Sciences in Q1 2017 and held it in 3 quarters.
  • DAFNA Capital Management's SELLAS Life Sciences position peaked at $28K in Q1 2017.
  • 24 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q4 2017.

Based on DAFNA Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.